3uvo › Citations

The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases.

Figure 1.
Figure 2.
Figure 3.
Zhang P, Lee H, Brunzelle JS, Couture JF
OpenAccess logo Nucleic Acids Res 40 4237-46 (2012)
Related entries: 3uvk, 3uvl, 3uvm, 3uvn

Cited: 71 times
EuropePMC logo PMID: 22266653

Abstract

In mammals, the SET1 family of lysine methyltransferases (KMTs), which includes MLL1-5, SET1A and SET1B, catalyzes the methylation of lysine-4 (Lys-4) on histone H3. Recent reports have demonstrated that a three-subunit complex composed of WD-repeat protein-5 (WDR5), retinoblastoma-binding protein-5 (RbBP5) and absent, small, homeotic disks-2-like (ASH2L) stimulates the methyltransferase activity of MLL1. On the basis of studies showing that this stimulation is in part controlled by an interaction between WDR5 and a small region located in close proximity of the MLL1 catalytic domain [referred to as the WDR5-interacting motif (Win)], it has been suggested that WDR5 might play an analogous role in scaffolding the other SET1 complexes. We herein provide biochemical and structural evidence showing that WDR5 binds the Win motifs of MLL2-4, SET1A and SET1B. Comparative analysis of WDR5-Win complexes reveals that binding of the Win motifs is achieved by the plasticity of WDR5 peptidyl-arginine-binding cleft allowing the C-terminal ends of the Win motifs to be maintained in structurally divergent conformations. Consistently, enzymatic assays reveal that WDR5 plays an important role in the optimal stimulation of MLL2-4, SET1A and SET1B methyltransferase activity by the RbBP5-ASH2L heterodimer. Overall, our findings illustrate the function of WDR5 in scaffolding the SET1 family of KMTs and further emphasize on the important role of WDR5 in regulating global histone H3 Lys-4 methylation.

Articles - 3uvo mentioned but not cited (2)

  1. The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases. Zhang P, Lee H, Brunzelle JS, Couture JF. Nucleic Acids Res 40 4237-4246 (2012)
  2. Impact of WIN site inhibitor on the WDR5 interactome. Guarnaccia AD, Rose KL, Wang J, Zhao B, Popay TM, Wang CE, Guerrazzi K, Hill S, Woodley CM, Hansen TJ, Lorey SL, Shaw JG, Payne WG, Weissmiller AM, Olejniczak ET, Fesik SW, Liu Q, Tansey WP. Cell Rep 34 108636 (2021)


Reviews citing this publication (23)

  1. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Rao RC, Dou Y. Nat Rev Cancer 15 334-346 (2015)
  2. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Herz HM, Garruss A, Shilatifard A. Trends Biochem Sci 38 621-639 (2013)
  3. The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation. Stavast CJ, Erkeland SJ. Cells 8 E1465 (2019)
  4. Inhibitors of Protein Methyltransferases and Demethylases. Kaniskan HÜ, Martini ML, Jin J. Chem Rev 118 989-1068 (2018)
  5. WRAD: enabler of the SET1-family of H3K4 methyltransferases. Ernst P, Vakoc CR. Brief Funct Genomics 11 217-226 (2012)
  6. Moonlighting with WDR5: A Cellular Multitasker. Guarnaccia AD, Tansey WP. J Clin Med 7 E21 (2018)
  7. On WD40 proteins: propelling our knowledge of transcriptional control? Migliori V, Mapelli M, Guccione E. Epigenetics 7 815-822 (2012)
  8. Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin. Bochyńska A, Lüscher-Firzlaff J, Lüscher B. Cells 7 E17 (2018)
  9. Mind the methyl: methyllysine binding proteins in epigenetic regulation. Wagner T, Robaa D, Sippl W, Jung M. ChemMedChem 9 466-483 (2014)
  10. Targeting human SET1/MLL family of proteins. Vedadi M, Blazer L, Eram MS, Barsyte-Lovejoy D, Arrowsmith CH, Hajian T. Protein Sci 26 662-676 (2017)
  11. The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer. Lu K, Tao H, Si X, Chen Q. Front Oncol 8 502 (2018)
  12. Epigenetic targets and drug discovery: part 1: histone methylation. Liu Y, Liu K, Qin S, Xu C, Min J. Pharmacol Ther 143 275-294 (2014)
  13. Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer. Zaidi SK, Frietze SE, Gordon JA, Heath JL, Messier T, Hong D, Boyd JR, Kang M, Imbalzano AN, Lian JB, Stein JL, Stein GS. Mol Cell Biol 37 e00352-17 (2017)
  14. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Wang Z, Patel DJ. Q Rev Biophys 46 349-373 (2013)
  15. The complex activities of the SET1/MLL complex core subunits in development and disease. Jiang H. Biochim Biophys Acta Gene Regul Mech 1863 194560 (2020)
  16. The many facets of MLL1 regulation. Zhang P, Bergamin E, Couture JF. Biopolymers 99 136-145 (2013)
  17. Regulation of neuronal survival by DNA methyltransferases. Symmank J, Zimmer G. Neural Regen Res 12 1768-1775 (2017)
  18. SET1/MLL family of proteins: functions beyond histone methylation. Sugeedha J, Gautam J, Tyagi S. Epigenetics 16 469-487 (2021)
  19. Structural Paradigms in the Recognition of the Nucleosome Core Particle by Histone Lysine Methyltransferases. Janna A, Davarinejad H, Joshi M, Couture JF. Front Cell Dev Biol 8 600 (2020)
  20. Keeping them all together: β-propeller domains in histone methyltransferase complexes. Bergamin E, Blais A, Couture JF. J Mol Biol 426 3363-3375 (2014)
  21. Roles of the Core Components of the Mammalian miRISC in Chromatin Biology. La Rocca G, Cavalieri V. Genes (Basel) 13 414 (2022)
  22. The role of Trithorax family regulating osteogenic and Chondrogenic differentiation in mesenchymal stem cells. Ma Q, Song C, Yin B, Shi Y, Ye L. Cell Prolif 55 e13233 (2022)
  23. Chemically induced degradation of epigenetic targets. Kabir M, Yu X, Kaniskan HÜ, Jin J. Chem Soc Rev 52 4313-4342 (2023)

Articles citing this publication (46)



Quick links